Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentered, Single-group Phase 2, Exploratory, Open-label Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in the Treatment of Adult Participants With Immunoglobulin A Nephropathy (IgAN)

NCT05856760 is registered in ClinicalTrials.gov with Travere Therapeutics, Inc. as lead sponsor.

NCT NCT05856760
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05856760 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentered, Single-group Phase 2, Exploratory, Open-label Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in the Treatment of Adult Participants With Immunoglobulin A Nephropathy (IgAN)
Lead sponsor
Travere Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
May 19, 2023
Completion date
October 25, 2024
Enrollment
48 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

immunoglobulin a nephropathy